Prelude Therapeutics Inc (PRLD) Stock Price, Quote & News

Company Profile

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat M...

Industry: Biotechnology

Sector: Healthcare

Phone: 302 467 1280

Website: preludetx.com

Address:

175 Innovation Boulevard, Wilmington, United States

TMC101 Jun. 24 at 5:04 PM

$PRLD 4.47

0 · Reply

Jaybird827 Jun. 24 at 12:54 PM

$PRLD let’s get this back to 5

0 · Reply

Biotech_Pharma_Investor Jun. 8 at 12:26 PM

https://www.businesswire.com/news/home/20260608808565/en/Johnson-Johnson-to-Acquire-Firefly-Bio-Inc.-to-Expand-Oncology-Pipeline-with-Novel-Degrader-Antibody-Conjugate-Platform DAC platform acquisition $NRIX $CCCC $PRLD

0 · Reply

exp8triot Jun. 4 at 2:31 PM

$PRLD I won't become a believer in this until its past $10

0 · Reply

Trader1141 Jun. 4 at 10:33 AM

$STI $MLEC $PRLD $AUUD 🔥 🔥🔥🔥🔥🔥🔥

1 · Reply

trad0r83 Jun. 1 at 2:08 PM

$PRLD Very promising!

0 · Reply

exp8triot May. 22 at 2:34 PM

$PRLD this stock sucks pumpndump scheme here.

2 · Reply

LabPsycho May. 21 at 8:14 PM

$PRLD @Jaybird827 read between the lines... https://preludetx.com/wp-content/uploads/2026/04/AACR-2026-Prelude-Poster-5793-Final.pdf

3 · Reply

elitechrisvp May. 6 at 4:31 PM

$IBRX nice moves $SLS $PRLD

0 · Reply

Jaybird827 May. 6 at 12:25 AM

$PRLD we need some news

2 · Reply

Prelude Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 9, 2026, 8:30 AM EDT - 15 days ago

Prelude Therapeutics Transcript: AGM 2026

Jun 3, 2026, 12:15 PM EDT - 21 days ago

Prelude Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

2026-05-15T09:13:07.000Z - 5 weeks ago

Prelude Therapeutics initiated with Early-Stage Biotech at Goldman Sachs

2026-05-12T11:55:16.000Z - 6 weeks ago

Prelude Therapeutics reports Q1 EPS (13c), consensus (27c)

May 12, 2026, 7:01 AM EDT - 6 weeks ago

Prelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 12, 2026, 7:00 AM EDT - 6 weeks ago

Prelude Therapeutics Earnings release: Q1 2026

May 12, 2026, 7:00 AM EDT - 6 weeks ago

Prelude Therapeutics Quarterly report: Q1 2026

May 11, 2026, 7:00 AM EDT - 6 weeks ago

Prelude Therapeutics Slides: Corporate presentation

2026-05-04T11:35:31.000Z - 7 weeks ago

Prelude Therapeutics initiated with a Buy at D. Boral Capital

Apr 29, 2026, 8:00 AM EDT - 2 months ago

Prelude Therapeutics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 2 months ago

Prelude Therapeutics Proxy statement: Proxy filing

2026-04-27T11:53:08.000Z - 2 months ago

Prelude Therapeutics price target raised to $8 from $5 at H.C. Wainwright

Apr 20, 2026, 7:00 AM EDT - 2 months ago

Prelude Therapeutics Slides: Corporate presentation

2026-04-20T10:34:29.000Z - 2 months ago

Prelude Therapeutics presents new preclinical data from PRT13722 study

Apr 20, 2026, 6:30 AM EDT - 2 months ago

Prelude Therapeutics Announces Pricing of $90.0 Million Underwritten Offering

Apr 20, 2026, 6:00 AM EDT - 2 months ago

Prelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at American Association for Cancer Research (AACR) Annual Meeting 2026

2026-04-15T11:51:11.000Z - 2 months ago

Prelude Therapeutics announces Charles Morris as chief medical officer

Apr 15, 2026, 7:30 AM EDT - 2 months ago

Prelude Therapeutics Announces the Appointment of Charles Morris, M.D. as Chief Medical Officer

2026-03-18T18:55:15.000Z - 3 months ago

Prelude Therapeutics management to meet with Citizens

Mar 17, 2026, 4:31 PM EDT - 3 months ago

Prelude Therapeutics Announces Acceptance of Preclinical Abstract for PRT13722, a First-in-Class Oral KAT6A Selective Degrader at the 2026 AACR Annual Meeting

2026-03-11T09:15:25.000Z - 3 months ago

Prelude Therapeutics price target raised to $6 from $3 at Citizens

Mar 10, 2026, 3:25 PM EDT - 3 months ago

Prelude Therapeutics Transcript: Conference

Mar 10, 2026, 8:00 AM EDT - 3 months ago

Prelude Therapeutics Annual report: Q4 2025

Mar 10, 2026, 8:00 AM EDT - 3 months ago

Prelude Therapeutics Earnings release: Q4 2025

2026-03-10T11:10:26.000Z - 3 months ago

Prelude Therapeutics reports FY25 EPS ($1.29) vs. ($1.68) last year

2026-03-10T11:10:14.000Z - 3 months ago

Prelude Therapeutics sees cash runway into 2Q27

Mar 10, 2026, 7:01 AM EDT - 3 months ago

Prelude Therapeutics Reports Full Year 2025 Financial Results and Provides Program Outlook for 2026

Mar 9, 2026, 7:00 AM EDT - 3 months ago

Prelude Therapeutics Slides: Corporate presentation

2026-02-03T14:10:10.000Z - 5 months ago

Prelude receives FDA clearance for investigational IND for PRT12396

Feb 3, 2026, 9:00 AM EST - 5 months ago

Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application (IND) for PRT12396, a Mutant-selective JAK2V617F Inhibitor

2025-12-10T21:16:07.000Z - 7 months ago

Prelude Therapeutics files to sell 6.25M shares of common stock for holders

Dec 10, 2025, 7:00 AM EST - 7 months ago

Prelude Therapeutics Registration statement: Registration Filing

2025-12-07T18:15:23.000Z - 7 months ago

Prelude Therapeutics presents data at 2025 ASH meeting from MPN programs

Dec 6, 2025, 11:00 AM EST - 7 months ago

Prelude Therapeutics Presents Data at the 2025 ASH Annual Meeting from its Myeloproliferative Neoplasm (MPN) Programs

Nov 12, 2025, 8:00 AM EST - 8 months ago

Prelude Therapeutics Earnings Call Transcript: Q3 2025

Nov 12, 2025, 8:00 AM EST - 8 months ago

Prelude Therapeutics Quarterly report: Q3 2025

Nov 12, 2025, 8:00 AM EST - 8 months ago

Prelude Therapeutics Earnings release: Q3 2025

2025-11-12T12:22:24.000Z - 8 months ago

Prelude Therapeutics reports Q3 EPS (26c) vs. (43c) last year

2025-11-12T12:22:00.000Z - 8 months ago

Prelude Therapeutics sees cash runway into 2027

Nov 12, 2025, 7:01 AM EST - 8 months ago

Prelude Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

2025-11-04T12:35:42.000Z - 8 months ago

Prelude Therapeutics pauses development of SMARCA2 degrader program

2025-11-04T12:35:31.000Z - 8 months ago

Prelude Therapeutics sees cash runway into 2027

Nov 4, 2025, 7:05 AM EST - 8 months ago

Prelude Therapeutics Announces Strategic Business Update

Nov 4, 2025, 7:01 AM EST - 8 months ago

Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors

Nov 3, 2025, 9:01 AM EST - 8 months ago

Prelude Therapeutics Announces Publication of Abstracts for Presentation at the American Society of Hematology 67th Annual Meeting

Nov 3, 2025, 7:00 AM EST - 8 months ago

Prelude Therapeutics Slides: Corporate Presentation

Oct 17, 2025, 7:30 AM EDT - 8 months ago

Prelude Therapeutics Announces Appointment of Katina Dorton, J.D., MBA to its Board of Directors

Aug 14, 2025, 7:00 AM EDT - 11 months ago

Prelude Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 14, 2025, 7:00 AM EDT - 11 months ago

Prelude Therapeutics Quarterly report: Q2 2025

Aug 14, 2025, 7:00 AM EDT - 11 months ago

Prelude Therapeutics Earnings release: Q2 2025

Jun 11, 2025, 9:20 AM EDT - 1 year ago

Prelude Therapeutics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 5, 2025, 3:10 PM EDT - 1 year ago

Prelude Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

Jun 2, 2025, 7:30 AM EDT - 1 year ago

Prelude Therapeutics to Participate in Upcoming Healthcare Conferences

May 7, 2025, 11:00 AM EDT - 1 year ago

Prelude Therapeutics Transcript: The Citizens JMP Life Sciences Conference 2025

May 6, 2025, 4:05 PM EDT - 1 year ago

Prelude Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 6, 2025, 4:00 PM EDT - 1 year ago

Prelude Therapeutics Quarterly report: Q1 2025

May 6, 2025, 4:00 PM EDT - 1 year ago

Prelude Therapeutics Earnings release: Q1 2025

May 1, 2025, 7:30 AM EDT - 1 year ago

Prelude Therapeutics to Participate in Citizens Life Sciences Conference

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Prelude Therapeutics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Prelude Therapeutics Proxy statement: Proxy Filing

Apr 25, 2025, 4:05 PM EDT - 1 year ago

Prelude Announces Presentations at 2025 AACR Annual Meeting

Apr 11, 2025, 8:00 AM EDT - 1 year ago

Prelude Therapeutics Proxy statement: Proxy Filing

Mar 11, 2025, 12:30 PM EDT - 1 year ago

Prelude Therapeutics Transcript: Barclays 27th Annual Global Healthcare Conference

Mar 10, 2025, 7:30 AM EDT - 1 year ago

Prelude Therapeutics Reports Full Year 2024 Financial Results and Provides Program Outlook for 2025

Mar 10, 2025, 7:00 AM EDT - 1 year ago

Prelude Therapeutics Annual report: Q4 2024

Mar 10, 2025, 7:00 AM EDT - 1 year ago

Prelude Therapeutics Earnings release: Q4 2024

Mar 5, 2025, 7:30 AM EST - 1 year ago

Prelude Therapeutics to Participate in Barclays 27th Annual Global Healthcare Conference

$Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies$

Dec 11, 2024, 7:30 AM EST - 1 year ago

Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies

Dec 2, 2024, 11:30 AM EST - 1 year ago

Prelude Therapeutics Transcript: The Citizens JMP Hematology and Oncology Summit Conference

Nov 27, 2024, 7:30 AM EST - 1 year ago

Prelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology Summit

Nov 5, 2024, 6:00 PM EST - 1 year ago

Prelude Therapeutics Quarterly report: Q3 2024

Nov 5, 2024, 6:00 PM EST - 1 year ago

Prelude Therapeutics Earnings release: Q3 2024

Oct 24, 2024, 7:30 AM EDT - 1 year ago

Prelude Therapeutics Presents New Data from SMARCA Degrader Portfolio at the 36th EORTC-NCI-AACR Symposium

Oct 9, 2024, 7:30 AM EDT - 1 year ago

Prelude Therapeutics Announces Publication of Abstracts for Presentation at the 36th EORTC-NCI-AACR Symposium

Sep 13, 2024, 12:00 PM EDT - 1 year ago

Prelude Therapeutics Transcript: Study Update

Sep 13, 2024, 12:00 PM EDT - 1 year ago

Prelude Therapeutics Press release: Study Update

Sep 13, 2024, 12:00 PM EDT - 1 year ago

Prelude Therapeutics Slides: Study Update

Sep 13, 2024, 10:00 AM EDT - 1 year ago

Prelude Therapeutics' SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial

Sep 9, 2024, 7:30 AM EDT - 1 year ago

Prelude Therapeutics Announces Publication of Abstract for Presentation at the European Society of Medical Oncology (ESMO) Congress 2024

Aug 12, 2024, 7:01 AM EDT - 2 years ago

Prelude Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 12, 2024, 7:00 AM EDT - 2 years ago

Prelude Therapeutics Quarterly report: Q2 2024

Aug 12, 2024, 7:00 AM EDT - 2 years ago

Prelude Therapeutics Earnings release: Q2 2024

Jul 9, 2024, 7:30 AM EDT - 2 years ago

Prelude Therapeutics Announces Clinical Collaboration with Merck to Evaluate PRT3789 in Combination with KEYTRUDA® (pembrolizumab) in Patients with SMARCA4-Mutated Cancers

Jun 12, 2024, 10:40 AM EDT - 2 years ago

Prelude Therapeutics Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

Jun 6, 2024, 1:30 PM EDT - 2 years ago

Prelude Therapeutics Transcript: Jefferies 2024 Global Healthcare Conference

May 30, 2024, 8:00 AM EDT - 2 years ago

Prelude Therapeutics Registration statement: Registration Filing

May 14, 2024, 1:00 PM EDT - 2 years ago

Prelude Therapeutics Transcript: The Citizens JMP Life Sciences Conference

May 9, 2024, 7:01 AM EDT - 2 years ago

Prelude Therapeutics to Participate in Citizens JMP Life Sciences Conference

May 7, 2024, 7:01 AM EDT - 2 years ago

Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 7, 2024, 7:00 AM EDT - 2 years ago

Prelude Therapeutics Quarterly report: Q1 2024

May 7, 2024, 7:00 AM EDT - 2 years ago

Prelude Therapeutics Earnings release: Q1 2024

May 6, 2024, 8:00 AM EDT - 2 years ago

Prelude Therapeutics Registration statement: Registration Filing

Apr 26, 2024, 8:00 AM EDT - 2 years ago

Prelude Therapeutics Proxy statement: Proxy Filing

Apr 26, 2024, 8:00 AM EDT - 2 years ago

Prelude Therapeutics Proxy statement: Proxy Filing

Apr 9, 2024, 4:35 PM EDT - 2 years ago

Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting

Mar 13, 2024, 3:05 PM EDT - 2 years ago

Prelude Therapeutics Transcript: Barclays 26th Annual Global Healthcare Conference 2024

Mar 5, 2024, 4:45 PM EST - 2 years ago

Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual Meeting

Feb 29, 2024, 4:05 PM EST - 2 years ago

Prelude Therapeutics to Participate in Barclays Global Healthcare Conference

Feb 16, 2024, 7:00 AM EST - 2 years ago

Prelude Therapeutics Registration statement: Registration Filing

Feb 15, 2024, 4:30 PM EST - 2 years ago

Prelude Therapeutics Annual report: Q4 2023

Feb 15, 2024, 4:30 PM EST - 2 years ago

Prelude Therapeutics Earnings release: Q4 2023

Feb 15, 2024, 4:05 PM EST - 2 years ago

Prelude Therapeutics Reports Full Year 2023 Financial Results and Outlines Key Objectives for 2024

Dec 11, 2023, 9:34 AM EST - 2 years ago

Prelude Therapeutics Announces $25 Million Private Placement

Nov 1, 2023, 4:10 PM EDT - 2 years ago

Prelude Announces Strategic Pipeline Progress and Updates, including its Partnership with AbCellera, and Reports Third Quarter Financial Results

Nov 1, 2023, 4:00 PM EDT - 2 years ago

Prelude Therapeutics Quarterly report: Q3 2023

Nov 1, 2023, 4:00 PM EDT - 2 years ago

Prelude Therapeutics Earnings release: Q3 2023

Oct 14, 2023, 12:30 PM EDT - 2 years ago

Prelude Announces Multiple Clinical and Preclinical Poster Presentations at AACR-NCI-EORTC International Conference

Sep 12, 2023, 4:55 PM EDT - 3 years ago

Prelude Therapeutics Transcript: Morgan Stanley 21st Annual Global Healthcare Conference 2023

Sep 6, 2023, 4:30 PM EDT - 3 years ago

Prelude Therapeutics Transcript: Wells Fargo Securities Healthcare Conference 2023

Aug 29, 2023, 8:30 AM EDT - 3 years ago

Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in September

Aug 3, 2023, 8:00 AM EDT - 3 years ago

Prelude Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update

Aug 3, 2023, 7:00 AM EDT - 3 years ago

Prelude Therapeutics Quarterly report: Q2 2023

Aug 3, 2023, 7:00 AM EDT - 3 years ago

Prelude Therapeutics Earnings release: Q2 2023

May 31, 2023, 8:30 AM EDT - 3 years ago

Prelude Therapeutics To Participate in Jefferies Healthcare Conference

May 17, 2023, 4:08 PM EDT - 3 years ago

Prelude Therapeutics Announces Launch of Proposed Public Offering

May 8, 2023, 8:30 AM EDT - 3 years ago

Prelude Therapeutics Announces First Quarter 2023 Financial Results and Operations Update

May 8, 2023, 7:00 AM EDT - 3 years ago

Prelude Therapeutics Quarterly report: Q1 2023

May 8, 2023, 7:00 AM EDT - 3 years ago

Prelude Therapeutics Earnings release: Q1 2023

Apr 28, 2023, 8:00 AM EDT - 3 years ago

Prelude Therapeutics Proxy statement: Proxy Filing

Apr 28, 2023, 8:00 AM EDT - 3 years ago

Prelude Therapeutics Proxy statement: Proxy Filing

Apr 27, 2023, 8:30 AM EDT - 3 years ago

Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in May

Apr 18, 2023, 8:00 AM EDT - 3 years ago

Prelude Therapeutics Proxy statement: Proxy Filing

Apr 11, 2023, 8:30 AM EDT - 3 years ago

Prelude Therapeutics to Present at American Association for Cancer Research 2023 Conference

Mar 15, 2023, 8:30 AM EDT - 3 years ago

Prelude Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update

Mar 15, 2023, 8:00 AM EDT - 3 years ago

Prelude Therapeutics Announces Clinical Trial Collaboration with BeiGene to Evaluate PRT2527 in Combination with Zanubrutinib in Hematologic Cancers

Mar 15, 2023, 8:00 AM EDT - 3 years ago

Prelude Therapeutics Annual report: Q4 2022

Mar 15, 2023, 8:00 AM EDT - 3 years ago

Prelude Therapeutics Earnings release: Q4 2022

Feb 9, 2023, 9:05 AM EST - 3 years ago

Prelude Therapeutics To Participate in Two Upcoming Healthcare Investor Conferences

TMC101 Jun. 24 at 5:04 PM

$PRLD 4.47

0 · Reply

Jaybird827 Jun. 24 at 12:54 PM

$PRLD let’s get this back to 5

0 · Reply

Biotech_Pharma_Investor Jun. 8 at 12:26 PM

0 · Reply

exp8triot Jun. 4 at 2:31 PM

$PRLD I won't become a believer in this until its past $10

0 · Reply

Trader1141 Jun. 4 at 10:33 AM

$STI $MLEC $PRLD $AUUD 🔥 🔥🔥🔥🔥🔥🔥

1 · Reply

trad0r83 Jun. 1 at 2:08 PM

$PRLD Very promising!

0 · Reply

exp8triot May. 22 at 2:34 PM

$PRLD this stock sucks pumpndump scheme here.

2 · Reply

LabPsycho May. 21 at 8:14 PM

$PRLD @Jaybird827 read between the lines... https://preludetx.com/wp-content/uploads/2026/04/AACR-2026-Prelude-Poster-5793-Final.pdf

3 · Reply

elitechrisvp May. 6 at 4:31 PM

$IBRX nice moves $SLS $PRLD

0 · Reply

Jaybird827 May. 6 at 12:25 AM

$PRLD we need some news

2 · Reply

LabPsycho Apr. 30 at 8:54 PM

$PRLD I note in their poster PRLD using WuXi AppTech (as did ERAS - check the recent news). Makes me wonder if, over the next year PRLD could be like carbon copy of ERAS move the past the past 5 months. 🤷‍♀️ "Acknowledgments: This study was funded by Prelude Therapeutics Incorporated. Data provided by CrownBio Sciences, WuXi AppTech, Pharmaron, Discovery Life Sciences, IQ Proteomics, and Novogene."

0 · Reply

BioRich Apr. 30 at 7:56 PM

$SLS $ALT should have bought $PRLD instead. I''ve made 24% in less than 24 hours. Not bad. Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems (like $PRLD and $KYTX) and learn. Let's make some (more) money. Cheers! $XBI

0 · Reply

BioRich Apr. 30 at 6:53 PM

$PRLD Thanks to a colleague for putting this on on my radar. Caught a dip yesterday at $4.18 and started a position. Looking good so far. Let's see how this plays out. I'm happy with the 18% 24-hour bump. Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn (several tickers I eventually follow are shared with me by colleagues and/or followers). Let's make some (more) money. Cheers!

0 · Reply

1AMBITIOUSSAVAGE Apr. 30 at 6:17 PM

$PRLD $AKAN NWGL - somethingcooking HOLD

0 · Reply

elitechrisvp Apr. 30 at 6:10 PM

$IBRX and $SLS and $PRLD dood stuff ✅️👍

0 · Reply

LabPsycho Apr. 29 at 5:19 PM

$PRLD @BillionerOfKing The problem I see with this strategy is you are not taking into account the enourmous spreads in many of these biotech options. The stock would have to move +/-80% before you broke even.

0 · Reply

LabPsycho Apr. 29 at 5:11 PM

$PRLD @chole1 I wonder if the ERAS situation the past few days has thrown a wet blanket on biotech companies doing protein degraders / glues, etc?

0 · Reply

BillionerOfKing Apr. 28 at 2:26 PM

$PRLD Current Stock Price: $4.54 Contracts to trade: $5.0 PRLD May 15 2026 Call Entry: $0.15 Exit: $0.25 ROI: 66% Hold ~30 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

DARKP00L Apr. 27 at 11:59 AM

$PRLD 07:57 on Apr. 27 2026 HC Wainwright & Co. Maintains Buy on Prelude Therapeutics, Raises Price Target to $8 #tradeideas

0 · Reply

chole1 Apr. 27 at 11:51 AM

$PRLD LLY buying private company Ajax Therapeutics for up to USD 2.3bn, for yet anothe Jak2i... Lets go PRLD!

0 · Reply

vu_jade Apr. 24 at 7:34 PM

$PRLD Top two holders: Orbimed Baker Brothers Couple of retards

0 · Reply

Jaybird827 Apr. 24 at 2:58 PM

$PRLD with all these shares being bought, how many shares can be remaining?

0 · Reply

Market Cap	348.85M
Revenue (ttm)	12.14M
Net Income (ttm)	-99.50M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-819.60%
Debt to Equity Ratio	0.00

Volume	232,400
Avg Vol	447,356
Day's Range	N/A - N/A
Shares Out	79.65M
Stochastic %K	48%
Beta	1.00
Analysts	Strong Sell
Price Target	$8.00